Istvan Karadi, MD, PhD; Sarolta Karpati, DSc; Laszlo Romics, DSc
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Karadi I., Karpati S., Romics L.; Aspirin in the Management of Recurrent Herpes Simplex Virus Infection. Ann Intern Med. 1998;128:696-697. doi: 10.7326/0003-4819-128-8-199804150-00027
Download citation file:
Published: Ann Intern Med. 1998;128(8):696-697.
TO THE EDITOR:
Recurrent facial-oral or genital herpes simplex virus (HSV-1 and HSV-2) infections affect 28% and 1.1% of the population of college students in the United States, respectively . The painful symptoms can disturb usual activities, and complete recovery often takes 8 to 9 days.
A 45-year-old man with severe recurrent herpes labialis had a myocardial infarction and began receiving aspirin, 125 mg/d. After 3 months, the patient reported complete disappearance of the herpetic episodes. Aspirin was his only new medication.
To explore the effect of aspirin, we recruited 21 volunteers with recurrent HSV infection (mean age ±SD, 29 ± 10 years; 14 were women and 7 were men); 19 had herpes labialis, and 2 had herpes genitalis. Patients immediately began receiving 125 mg of aspirin daily at the first evidence of symptomatic HSV recurrence. Nine of these volunteers continued to take aspirin for several months. We also observed 21 sex- and age-matched persons with recurrent HSV infection who had not taken any anti-inflammatory or antiviral drugs. The aspirin-treated patients had significantly fewer days of active HSV infections than did the controls (4.71 ± 0.95 days compared with 8.09 ± 0.99 days; P < 0.001). All aspirin recipients reported milder skin involvement than they had experienced previously. Patients receiving long-term aspirin therapy had longer symptom-free periods.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only